Immunotherapy has potential as a future adjunct to standard of care; cancer vaccines such as the dendritic cell (DC) and epidermal growth factor receptor (EGFR) vaccines have shown encouraging results in phase I and II clinical trials and raise the possibility of personalized peptide vaccines or even individualized whole tumor vaccines as more targeted alternatives for immunotherapy. This evidence concerns the gene EGFR and cancer.